Literature DB >> 10580183

Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects.

T Shoji1, Y Nishizawa, M Fukumoto, K Shimamura, J Kimura, H Kanda, M Emoto, T Kawagishi, H Morii.   

Abstract

Oxidized low density lipoprotein (oxLDL) has been implicated in the pathogenesis of atherosclerosis. Recent studies have shown that immunization of animals with oxLDL results in suppression of atherogenesis. Antibody against oxLDL (oxLDL Ab) is detectable in human sera, although its biological significance is not well established. We examined the relationship between oxLDL Ab titer and circulating oxLDL level in 130 healthy Japanese subjects. OxLDL was measured as apolipoprotein (apo) B-containing lipoproteins carrying oxidized phosphatidylcholines by a sensitive ELISA. IgG class oxLDL Ab titer was measured by ELISA. Plasma oxLDL concentration was very low and it corresponded on average to one to two out of 1000 apoB-containing lipoproteins in plasma. Plasma oxLDL correlated positively with LDL cholesterol and inversely with oxLDL Ab titer. These associations remained significant and independent in multiple regression analysis including age, gender, smoking, and high-density lipoprotein cholesterol. These data indicate that healthy subjects have a very low concentration of oxLDL in the circulation, and that oxLDL Ab titer is in an inverse relationship with plasma oxLDL concentration in this population. Although these results suggest that oxLDL Ab may play a role in maintaining the low level of plasma oxLDL, its role in atherogenesis awaits further studies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10580183     DOI: 10.1016/s0021-9150(99)00218-x

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  29 in total

1.  The autoantibody repertoire against copper- or macrophage-modified LDL differs in normolipidemics and hypercholesterolemic patients.

Authors:  Eva C Fernvik; Daniel F J Ketelhuth; Momtchilo Russo; Magnus Gidlund
Journal:  J Clin Immunol       Date:  2004-03       Impact factor: 8.317

Review 2.  Intravenous immunoglobulin and atherosclerosis.

Authors:  Eiji Matsuura; Kazuko Kobayashi; Katsumi Inoue; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

3.  Relation between plasma oxLDL antibodies and oxLDL in the circulation.

Authors:  Yan Wang; Xueqiang Fang; Shumei Wang; Yueqiu Feng; Jinghai Yin
Journal:  Inflammation       Date:  2006-12-02       Impact factor: 4.092

Review 4.  Dyslipidemia in patients with chronic and end-stage kidney disease.

Authors:  Jad Omran; Ashraf Al-Dadah; Kevin C Dellsperger
Journal:  Cardiorenal Med       Date:  2013-07-13       Impact factor: 2.041

5.  PPARgamma regulates adipocyte cholesterol metabolism via oxidized LDL receptor 1.

Authors:  Patricia C Chui; Hong-Ping Guan; Michael Lehrke; Mitchell A Lazar
Journal:  J Clin Invest       Date:  2005-07-07       Impact factor: 14.808

6.  Oxidative stress in children on hemodialysis: value of autoantibodies against oxidized low-density lipoprotein.

Authors:  Nurcan Cengiz; Esra Baskin; Nurzen Sezgin; Pinar Agras; Mehmet Haberal
Journal:  Pediatr Nephrol       Date:  2008-10-29       Impact factor: 3.714

Review 7.  Oxidative modification of LDL: its pathological role in atherosclerosis.

Authors:  Hiroyuki Itabe
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

8.  Curcumin eliminates oxidized LDL roles in activating hepatic stellate cells by suppressing gene expression of lectin-like oxidized LDL receptor-1.

Authors:  Qiaohua Kang; Anping Chen
Journal:  Lab Invest       Date:  2009-09-07       Impact factor: 5.662

Review 9.  Effects of inflammation on cholesterol metabolism: impact on systemic lupus erythematosus.

Authors:  Allison B Reiss
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

10.  Atherosclerosis risk factors in systemic lupus erythematosus.

Authors:  Surabhi Agarwal; Jennifer R Elliott; Susan Manzi
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.